# Esperion Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/esperion-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Ann Arbor, US
- Website: www.esperion.com
- Total disclosed funding: $45M
- Latest round: Series A (May 1, 2008)
- Investors on record: 9

## About

Esperion Therapeutics, Inc. develops innovative therapies to treat cardiovascular diseases, emphasizing the advancement of ACLY inhibitors to address significant patient needs in this area.Esperion Therapeutics specializes in creating treatments for cardiovascular conditions and is headquartered in Ann Arbor, US. Founded in June 2013, the company completed its IPO, raising USD 70 mn by pricing 5 million shares at USD 14 each. In March 2015, Esperion raised a total of USD 175 mn through a Private Placement/Follow on by selling 1.75 million shares at USD 100 each. The firm has conducted 9 deals up to the most recent in March 2015.Esperion Therapeutics, Inc. specializes in the development of innovative treatments for cardiovascular disease, offering two core products that have gained regulatory approval in both the United States and Europe. These treatments utilize a unique mechanism of action targeting ACLY biology, marking a significant advancement in cardiovascular disease management. The company's pioneering work has led to the introduction of the first ACLY inhibitor to the market, which is aimed at addressing the unmet needs of patients suffering from life-threatening cardiovascular conditions. Esperion's products are distributed globally, maximizing accessibility through strategic partnerships with commercial organizations to ensure effective delivery to healthcare providers and patients in need.Esperion Therapeutics generated revenue of USD 332.31 mn in 2024, with an EBITDA of USD 54.47 mn for the same year. The company generates revenue through the commercialization of its approved products, utilizing a B2B model that allows for efficient delivery of therapies while expanding its market presence globally.Esperion Therapeutics plans to launch new products targeting cardiovascular diseases with anticipated releases in the coming years, although specific dates are not disclosed. The company aims to expand its reach into new markets, particularly focusing on regions with unmet treatment needs. The funding raised from the most recent deal in March 2015 will support these growth initiatives, enhancing both product development and market entry strategies.

## Funding rounds

- Series A, May 1, 2008, $23M — Alta Partners, Domain Associates, Aisling Capital, Arboretum Ventures
- Series C, Jan 17, 2000, $22M — Oak Investment Partners, TL Ventures, HealthCap, Canaan Partners, Avalon Ventures

## Investors

- Oak Investment Partners (https://capitalatlas.ai/funds/oak-investment-partners) — Series C
- TL Ventures (https://capitalatlas.ai/funds/tl-ventures) — Series C
- HealthCap — Series C
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series C
- Avalon Ventures (https://capitalatlas.ai/funds/avalon-ventures) — Series C
- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series A
- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series A
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series A
- Arboretum Ventures (https://capitalatlas.ai/funds/arboretum-ventures) — Series A